Key Performance
More- Earnings Score: 85
- Momentum Score: 31
- True Yield: N/A
- Financial Health Score: 63
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Hims & Hers Health faces a securities class action lawsuit after the FTC alleged the telehealth provider shared consumers' sensitive health information with third-party advertising platforms while claiming to maintain privacy, and deceived users about billing and cancellation practices. The stock declined 14.73% on July 29, 2026, following the FTC announcement. Investors who purchased securities between August 4, 2025 and July 29, 2026 have until November 2, 2026 to file lead plaintiff applications.
10/20/2026, 11:31 PM • GlobeNewswire
A class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly making false and misleading statements regarding consumer health data sharing with third-party advertising platforms, charging for prescriptions immediately after intake forms despite promising provider consultation, and failing to disclose regulatory scrutiny and potential penalties. Investors who purchased Hims securities between August 4, 2025 and July 29, 2026 have until November 2, 2026 to apply as lead plaintiff.
10/20/2026, 6:58 PM • GlobeNewswire
A class action lawsuit has been filed against Hims & Hers Health, Inc. alleging securities fraud. The complaint claims the company made false statements about consumer data privacy, misrepresented prescription charging practices, and failed to disclose regulatory risks. Investors who purchased Hims securities between August 4, 2025 and July 29, 2026 are encouraged to join the case.
10/19/2026, 11:00 PM • GlobeNewswire
Hims Is Reaching the Three Million Member Milestone
Hims & Hers Health is approaching a three million member milestone, with several catalysts positioned to sustain robust growth. The company operates in the healthcare industry, which is described as ripe for disruption.
10/19/2026, 9:25 PM • The Motley Fool
Rosen Law Firm is urging investors who purchased Hims & Hers Health securities between August 4, 2025 and July 29, 2026 to secure legal counsel before the November 2, 2026 lead plaintiff deadline. The class action lawsuit alleges that Hims made materially false statements regarding consumer health data sharing with third-party advertisers, premature prescription charges, and regulatory risks that were not properly disclosed to investors.
10/19/2026, 7:24 PM • GlobeNewswire
Rosen Law Firm has filed securities class action lawsuits against Millrose Properties, Hims & Hers Health, and Doximity for alleged disclosure failures and misleading statements to investors. Millrose Properties is accused of misrepresenting its business objectives and leasing properties at a loss. Investors have until December 8, 2026 to move the court to serve as lead plaintiff.
10/16/2026, 6:27 PM • GlobeNewswire
Rosen Law Firm announces a securities class action lawsuit against Hims & Hers Health, Inc. for allegedly making false statements about data privacy practices and billing procedures. The lawsuit claims Hims shared consumer health information with third-party advertisers and charged for prescriptions immediately despite promising consultations with medical providers. Investors who purchased HIMS securities between August 4, 2025 and July 29, 2026 may be eligible for compensation. The lead plaintiff deadline is November 2, 2026.
10/16/2026, 6:10 PM • GlobeNewswire
A class action lawsuit has been filed against Hims & Hers Health, Inc. alleging securities fraud. The complaint claims the company made materially false statements regarding data privacy practices, prescription charging procedures, and failed to disclose regulatory scrutiny and potential penalties. Investors who purchased Hims securities between August 4, 2025 and July 29, 2026 are encouraged to join the case, with a lead plaintiff deadline of November 1, 2026.
10/15/2026, 11:00 PM • GlobeNewswire
Robbins Geller announces a class action lawsuit against Hims & Hers Health, Inc. for allegedly sharing consumers' health information with third-party advertising platforms and charging for prescriptions immediately after intake forms despite claiming personalized consultations. The FTC filed a lawsuit on July 29, 2026, leading to a 15% decline in Hims & Hers stock. Investors with substantial losses can seek lead plaintiff status before November 2, 2026.
10/15/2026, 7:00 AM • GlobeNewswire
Robbins LLP is reminding investors of a pending class action lawsuit against Hims & Hers Health, Inc. for allegedly sharing consumers' sensitive health information with advertising platforms while claiming privacy protection, and engaging in deceptive billing practices. The FTC filed a lawsuit on July 29, 2026, which caused HIMS stock to decline 14.73%. Investors who purchased securities between August 4, 2025 and July 29, 2026 may be eligible to participate, with a lead plaintiff deadline of November 2, 2026.
10/14/2026, 7:53 PM • GlobeNewswire
A class action securities fraud lawsuit has been filed against Hims & Hers Health, Inc. following an FTC lawsuit alleging the telehealth provider shared consumers' sensitive health information with third-party advertising platforms and engaged in deceptive billing practices. The stock declined 14.73% on July 29, 2026, following the FTC announcement. Investors who purchased HIMS securities between August 4, 2025 and July 29, 2026 have until November 2, 2026 to file a lead plaintiff motion.
10/14/2026, 2:35 PM • GlobeNewswire
Rosen Law Firm has filed securities class action lawsuits against multiple companies. The primary case involves Hims & Hers Health, Inc., alleging the company made false statements about data privacy, charged consumers for prescriptions without proper consultation, and failed to disclose regulatory scrutiny. The firm is seeking lead plaintiffs with a November 2, 2026 deadline. Similar lawsuits have been filed against Papa John's International and Millrose Properties.
10/13/2026, 8:52 PM • GlobeNewswire
Rosen Law Firm announces securities class action lawsuits against Papa John's International (PZZA) and other companies. The Papa John's lawsuit alleges the company made materially false statements about its transformation efforts, concealing that the process was taking longer than expected and failing to prevent market share losses. Investors who purchased stock during the class period may be eligible for compensation. The lead plaintiff deadline is November 2, 2026.
10/13/2026, 8:12 PM • GlobeNewswire
A class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly making false statements and failing to disclose that it shares consumers' health information with third-party advertising platforms and charges for prescriptions immediately after intake forms are submitted. The FTC, California, and Utah filed a separate lawsuit on July 29, 2026, resulting in a 14.73% stock price decline.
10/13/2026, 10:59 AM • GlobeNewswire
Rosen Law Firm is encouraging investors who purchased Hims & Hers Health, Inc. securities between August 4, 2025 and July 29, 2026 to join a class action lawsuit. The lawsuit alleges that Hims made materially false and misleading statements regarding data privacy practices, prescription charging procedures, and regulatory compliance, which subjected the company to potential fees and penalties.
10/11/2026, 7:14 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 10/21/2026
Company Profile
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, Australia, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. The company was formerly known as Hims, Inc. and changed its name to Hims & Hers Health, Inc. in January 2021. The company was founded in 2017 and is based in San Francisco, California.